Published in PLoS One on February 16, 2012
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer (2014) 0.96
Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells. J Clin Endocrinol Metab (2016) 0.86
Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer. BMC Cancer (2014) 0.82
Combined 2-deoxy glucose and metformin improves therapeutic efficacy of sodium-iodide symporter-mediated targeted radioiodine therapy in breast cancer cells. Breast Cancer (Dove Med Press) (2015) 0.78
Molecular mechanisms of 2, 3', 4, 4', 5-pentachlorobiphenyl-induced thyroid dysfunction in FRTL-5 cells. PLoS One (2015) 0.76
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2009) 3.35
The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med (2000) 3.01
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res (2010) 2.01
Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients. Ophthal Plast Reconstr Surg (2005) 1.58
Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab (2001) 1.54
An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology (1998) 1.34
Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology (1997) 1.32
Patterns of radioiodine uptake by the lactating breast. Eur J Nucl Med (1994) 1.28
The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf) (2002) 1.27
The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets (2010) 1.25
Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci U S A (2000) 1.23
Human melanoma cells express functional receptors for thyroid-stimulating hormone. Endocr Relat Cancer (2006) 1.23
Histone acetylation: where to go and how to get there. Epigenetics (2009) 1.21
Emerging MEK inhibitors. Expert Opin Emerg Drugs (2010) 1.16
Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. J Invest Dermatol (2002) 1.09
Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab (1998) 1.08
Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab (2009) 1.06
IQGAP1 plays an important role in the invasiveness of thyroid cancer. Clin Cancer Res (2010) 1.03
Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology (2005) 1.02
Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery (2002) 1.01
Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab (1999) 1.00
Whole-body scintigraphy with radioiodine-131. A comprehensive list of false-positives with some examples. Clin Nucl Med (1995) 0.99
Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab (1998) 0.99
Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. Thyroid (2000) 0.92
Frequency of hepatic visualization during I-131 imaging for metastatic thyroid carcinoma. Clin Nucl Med (1988) 0.92
Expression of the sodium iodide symporter in human kidney. Kidney Int (2001) 0.92
Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications. PLoS One (2009) 0.89
A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy. Curr Gene Ther (2002) 0.88
Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat Anticancer Drug Discov (2011) 0.87
The scope of false-positive iodine-131 images for thyroid carcinoma. Clin Nucl Med (1989) 0.85
The sodium-iodide symporter. Curr Drug Targets Immune Endocr Metabol Disord (2004) 0.84
Regulation of sodium/iodide symporter. Rev Endocr Metab Disord (2000) 0.83
Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor. J Clin Endocrinol Metab (2006) 0.80
Sodium/iodide symporter expression in primary lung cancer and comparison with glucose transporter 1 expression. Pathol Int (2009) 0.77
BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab (2008) 2.89
Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer (2013) 2.69
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res (2007) 2.61
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab (2011) 2.06
The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle (2012) 1.98
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid (2008) 1.93
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res (2011) 1.85
Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst (2013) 1.78
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) (2012) 1.77
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer (2006) 1.56
Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab (2009) 1.55
Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle (2013) 1.52
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab (2014) 1.52
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab (2005) 1.51
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab (2007) 1.47
DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Res (2005) 1.44
Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer (2008) 1.39
Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res (2007) 1.39
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res (2009) 1.31
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun (2010) 1.31
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab (2007) 1.19
MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle (2009) 1.17
Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer (2011) 1.16
BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer (2010) 1.14
Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle (2007) 1.14
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab (2007) 1.12
The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun (2010) 1.08
Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab (2009) 1.06
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab (2005) 1.04
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer (2008) 1.04
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab (2011) 1.04
IQGAP1 plays an important role in the invasiveness of thyroid cancer. Clin Cancer Res (2010) 1.03
BRAF V600E mutation and papillary thyroid cancer. JAMA (2013) 1.03
Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem (2013) 1.01
Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocr Pathol (2011) 0.99
BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management. Ann Surg Oncol (2009) 0.98
Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab (2015) 0.98
Genetic-targeted therapy of thyroid cancer: a real promise. Thyroid (2009) 0.97
Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer (2014) 0.96
BRAFV600E mutation and papillary thyroid cancer: chicken or egg? J Clin Endocrinol Metab (2012) 0.95
Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer (2013) 0.94
Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors. J Clin Endocrinol Metab (2007) 0.92
DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma. Endocr Relat Cancer (2013) 0.91
Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer (2008) 0.90
Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications. PLoS One (2009) 0.89
Mitochondrial DNA alterations in thyroid cancer. J Surg Oncol (2003) 0.88
The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression. J Clin Endocrinol Metab (2014) 0.88
Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer. J Clin Endocrinol Metab (2005) 0.86
Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma. Biochem Biophys Res Commun (2012) 0.83
Induction of heparanase-1 expression by mutant B-Raf kinase: role of GA binding protein in heparanase-1 promoter activation. Neoplasia (2010) 0.82
Absence of germline mutations in genes within the MAP kinase pathway in familial non-medullary thyroid cancer. Cell Cycle (2006) 0.81
Estrogen receptor α induces prosurvival autophagy in papillary thyroid cancer via stimulating reactive oxygen species and extracellular signal regulated kinases. J Clin Endocrinol Metab (2015) 0.81
Strong association of high urinary iodine with thyroid nodule and papillary thyroid cancer. Tumour Biol (2014) 0.80
Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit. J Clin Endocrinol Metab (2009) 0.80
Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer. Oncol Lett (2013) 0.79
Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer (2008) 0.79
BRAF V600E mutation and papillary thyroid cancer--in reply. JAMA (2013) 0.78
Association of Cigarette Smoking with Aberrant Methylation of the Tumor Suppressor Gene RARβ2 in Papillary Thyroid Cancer. Front Endocrinol (Lausanne) (2011) 0.78
Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification. PLoS One (2012) 0.77
Letter re: uncommon mutation but common amplifications of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab (2005) 0.76
Pituitary homeobox 2 in thyroid tumorigenesis: extension from its classical developmental role. Cell Cycle (2010) 0.75